Larvol Delta - Cirius-Therapeutics-phase-2b-data-of-MSDC0602K-for-the-treatment-of-NASH-accepted-as-a-latebreaking-oral-presentation-at-the-Liver-Meeting

MSDC-0602K - Cirius Therap

https://www.prnewswire.com/news-releases/cirius-therapeutics-phase-2b-data-of-msdc-0602k-for-the-treatment-of-nash-accepted-as-a-late-breaking-oral-presentation-at-the-liver-meeting-300942282.html

Oct 21, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next